Andrew Harrow

Andrew Harrow is a partner in the firm’s Life Sciences group. Andrew advises on a wide range of UK and cross-border transactions including joint ventures, mergers and acquisitions, reorganizations, initial public offerings, and fundraisings for listed and private companies internationally as well as general corporate and capital market matters. He has a particular interest in transactions in the life sciences, healthcare, and technology sectors.

Prior to joining Goodwin in 2018, Andrew was a partner at Dechert LLP.

Life Sciences Transactions

• Vicebio on its $100 million Series B financing led by by TCGX. Vicebio is focused on developing next-generation respiratory virus vaccines using the Molecular Clamp Technology
• SynAffix and its selling shareholders on its sale to Lonza. Under the terms of the sale and purchase agreement, Lonza have paid Synaffix’s shareholders an upfront payment of €100 million, with the potential for shareholders to receive an additional payment of up to €60 million contingent on financial performance
• Grey Wolf Therapeutics in its $49 million Series B financing to advance first-of-its-kind neoantigen creation approaches
• Syndesi Therapeutics and its selling shareholders on its sale to AbbVie Central Finance B.V. for an upfront consideration of $130 million with potential for shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones
• Enterprise Therapeutics Ltd on the demerger and subsequent acquisition of its TMEM16A potentiator portfolio by Roche for an upfront consideration of £75 million and significant potential milestone payments
• Inflazome Limited and its shareholders on the sale of 100% of its equity share capital to Roche for total initial consideration of €380 million
• Staten Biotechnology B.V. on its strategic collaboration with Novo Nordisk A/S to develop novel therapeutics for the treatment of triglyceride dyslipidemia, by way of an option to acquire structure
• Orchard Therapeutics plc in its $225 million initial public offering on NASDAQ
• Gadeta B.V. on its strategic collaboration with Kite Pharma Inc. to develop novel gamma delta T cell receptors therapies in various cancers together with the grant to Kite of an exclusive option to acquire Gadeta
• Prexton Therapeutics B.V. and its selling shareholders in its sale to global pharmaceutical company H. Lundbeck A/S for up to €905 million*
• The shareholders of Stat-Dx, a privately owned Spanish diagnostics company, on its sale to QIAGEN N.V., for $191 million (including milestones)*
• The shareholders of Ziarco Group Limited in connection with the sale of the company to Novartis*
• The shareholders of XO1 Limited (including Index Ventures) on the sale of XO1 Limited to Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson*
• The shareholders of biopharmaceutical company Covagen AG in relation to the sale of Covagen to the Janssen Pharmaceutical Companies of Johnson & Johnson*
• An international investment manager in connection with its participation in BioNTech AG’s $270 million Series A financing*
• ProFibrix B.V. in connection with its sale to NASDAQ-listed The Medicines Company*
• Auven Therapeutics on its acquisition of Spirogen and the subsequent sale of Spirogen to Medimmune/AstraZeneca*
• Nomura Code Securities in relation to Silence Therapeutic plc’s merger with Intradigm Corporation and its placing and offer for a subscription of shares*

Other Transactions

• KaNDy Therapeutics on its sale to Bayer for $425 million upfront with up to $450 million in development milestone payments and triple digit millions in commercial milestones
• Index Ventures and Accel in relation to the IPO of Funding Circle Holdings plc on the London Stock Exchange
• Capital Z Partners LP in connection with its acquisition of Prestige Insurance Holdings Limited (the largest privately owned insurance broker and managing general agent in Northern Ireland) and owner of Northern Ireland’s leading insurance broker Abbey Insurance
• Index Ventures, Greylock Partners, Redpoint Ventures, SM Trust and Vitruvian Partners (the majority shareholders of leading online takeaway service JustEat.com) in relation to the IPO of JustEat.com on the London Stock Exchange’s High Growth Segment and their subsequent sales of additional shares in JustEat in several tranches by way of various accelerated bookbuild processes*
• AIM-listed ACM Shipping Group plc in connection with its £150 million recommended merger with London Stock Exchange Main Market-listed Braemar Shipping Services plc, effected by way of scheme of arrangement*
• The Mohamed Al Fayed family trust in connection with the sale of Fulham Football Club to Shahid Khan, the CEO of Flex-N-Gate Group and owner of the NFL team, the Jacksonville Jaguars*
• Tilda Limited, a leading Basmati and specialty rice products company, and its shareholders on the sale of Tilda to NASDAQ-listed Hain Celestial Group, Inc*
• Kofax Limited, a leading provider of smart process applications for the business-critical First Mile of customer interactions, on its restructuring proposals creating a new holding company incorporated in Bermuda implemented by way of scheme of arrangement together with new premium listings on the Main Market of the London Stock Exchange and the NASDAQ Global Select Market*
• NYSE-listed FMC Corporation in its acquisition of Phytone Ltd., a natural colours producer based in the United Kingdom*
• PhotoBox, Europe’s largest online photo processing service, on its £120 million acquisition of Moonpig.com Limited and related group reorganisation, debt and equity financing*
• Liberty plc, the iconic Regent Street retail business, and its majority shareholder MWB Group Holdings plc in connection with its £71.5 million takeover by BlueGem Capital Partners LLP*
• The Republic of Serbia and Nomura, as financial advisor, on the privatisation of Vojvodjanska Banka Novi Sad and its €385 million sale to The National Bank of Greece*
• The Crown Estate in connection with its £680 million joint venture with British Land Co. plc*
• A NYSE-listed international conglomerate in connection with the acquisitions of various businesses in the United Kingdom*
• Altima Partners, as sponsor, and Campos Verdes Ltd. on its $613.2 million business combination with El Tejar SAACEI to form El Tejar Limited, one of the leading agribusinesses in Latin America*
• Capital Z Partners LP in connection with its acquisition from 3i plc of its interest in Jelf Group plc and associated subscription for new shares in Jelf Group plc*
• Spark Advisory Partners Limited, as nominated adviser, and WH Ireland Limited and Whitman Howard Limited, as joint brokers, on the admission to trading on AIM of IMIMobile plc, a leading global technology company*
• Shore Capital as nominated adviser and broker to SafeCharge International Group Limited, an international provider of payments services, risk management and IT solutions for online businesses, on its US$400 million (c.£242.6 million) IPO on AIM*
• Shore Capital & Corporate Limited and Shore Capital Stockbrokers Limited on an equity fundraising and debt restructuring by AIM-listed Styles & Wood plc*

* Denotes experience prior to joining Goodwin.

Andrew is listed as a recommended lawyer in The Legal 500 UK 2025 for Venture Capital, M&A, and Life Sciences and Healthcare. Clients note that ‘Andrew… is a stand-out. He is an exceptional professional and exhibits exemplary behaviour. He is always available and always pleasant’. He was also described as “brilliant” with respect to M&A work.

Andrew was also recognized for excellence in the 2024 and 2025 editions of The Best Lawyers in the United Kingdom.